The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
Jonathan Van Ness has candidly shared about his weight loss experience, shedding nearly 70 pounds using GLP-1 drugs while addressing body positivity concerns. He emphasizes feeling better through medication and Pilates. Health tracking apps like Shotlee can help monitor such progress.
Social media personality Anna Paul has responded to a detractor who pointed out what they believed was an 'Ozempic bruise' in a shared image. She clarified that the discoloration resulted from a cycling mishap, not the weight-loss medication. This incident follows earlier worries about her health after a relationship breakup.
Weight-loss injections such as Ozempic have altered festive meal preparations for many Brits. Recent studies show changes in buying habits and rising concerns among hosts. Health tracking tools can aid in monitoring these shifts.
As the new year begins, many Americans reflect on their weight goals, with 52% expressing a wish to shed pounds while just 26% are making real efforts. Women are more likely than men to perceive themselves as overweight and desire change. Long-term data shows consistent patterns in self-reported weight and ideals.
Health experts are expressing significant alarms over the promotion of virtual weight loss initiatives to those in fragile states. Advocacy organizations highlight indirect drug recommendations lacking adequate safeguards. Telehealth providers defend their practices while critics push for better regulation.
Revolutionary advancements in weight loss treatments, including medications like GLP-1 agonists and bariatric surgery, offer promising results but are often unaffordable. High expenses and limited insurance hinder access for many, turning health solutions into privileges. This exacerbates social disparities, demanding structural changes for equitable healthcare.
Novo Nordisk has earned a significant FDA victory with the approval of an oral version of Wegovy, aiming to simplify weight management for patients. This development could bolster the company's position against rivals like Eli Lilly, despite growing market pressures.
A common plant from Brazilian coastal regions has demonstrated potential in laboratory tests to alleviate arthritis symptoms by diminishing inflammation and safeguarding joint health. Researchers from several Brazilian universities conducted the study, highlighting its traditional uses and safety profile. While promising, further human trials are essential to confirm its effectiveness.
Experts in eating disorders express alarm over the swift introduction of GLP-1 weight-loss drugs through telehealth platforms and intense social media promotions by certain firms. One instance highlighted references to restrictive Australian regulations hindering detailed medication info for buyers. The Australia and New Zealand Academy for Eating Disorders fears such tactics might appeal to those who don't require the drugs.
